Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...

Bristol-Myers Squibb has said it will buy biotech MyoKardia in a $13.1 billion takeover that marks a step up in its development of cardiovascular drugs. The all-cash deal is mainly about MyoKardia’s ...

BMS will invest $2.3B in 600,000-square-foot manufacturing campus in Houston Facility expected to create 500 skilled jobs Construction slated to run from 2027 through 2030 Project part of BMS’ $40B US ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

British drugmaker AstraZeneca (AZ) is reportedly in talks to merge with U.S. company Bristol Myers Squibb (BMS). According to foreign media including the Financial Times (FT) on the 3rd (local time), ...

It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired Allergan, and Bristol Myers Squibb swallowed Celgene. While those $60 billion-plus ...

After earlier reports that AstraZeneca and New Jersey-based competitor Bristol Myers Squibb were exploring a mega merger, sources told Reuters the pharmaceutical giants will not consider a potential ...

The rumors of reported AstraZeneca–Bristol Myers merger discussions provide an opportunity to examine how multiple emerging capabilities may reshape corporate strategy, mergers and acquisitions, and ...

Everything is bigger in Texas. And so it is with Bristol Myers Squibb’s $2.3 billion investment in a manufacturing campus in Houston, which comes in at more than twice the price the company estimated ...

UK drugmaker AstraZeneca is in talks to combine with US rival Bristol Myers Squibb in a deal that would create one of the world’s biggest pharmaceutical groups, valued at nearly $400bn. The companies ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic agreement with Bristol Myers Squibb (BMS) to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.